Artivion, Inc. (NYSE:AORT) Stock Has Average Target Price of $44.83

Posted by George Bondi on Oct 14th, 2026

Shares of Artivion, Inc. (NYSE:AORT – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $44.83.

A number of equities research analysts recently issued reports on the company. Weiss Ratings lowered Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Canaccord Genuity Group increased their target price on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Citigroup reiterated a “market outperform” rating on shares of Artivion in a research note on Tuesday, July 21st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $44.00 target price on shares of Artivion in a research report on Monday, July 20th.

Read Our Latest Analysis on AORT

Insider Transactions at Artivion

In related news, SVP Andrew M. Green sold 11,480 shares of Artivion stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $24.97, for a total transaction of $286,655.60. Following the completion of the sale, the senior vice president owned 40,160 shares in the company, valued at $1,002,795.20. This trade represents a 22.23% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Jean F. Holloway sold 977 shares of Artivion stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total transaction of $27,834.73. Following the sale, the senior vice president owned 184,118 shares of the company’s stock, valued at $5,245,521.82. The trade was a 0.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 90,460 shares of company stock worth $2,557,366. Insiders own 6.30% of the company’s stock.

Hedge Funds Weigh In On Artivion

Hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc increased its position in shares of Artivion by 38.0% during the third quarter. Versant Capital Management Inc now owns 2,119 shares of the company’s stock worth $48,000 after acquiring an additional 584 shares during the period. Squarepoint Ops LLC raised its stake in shares of Artivion by 112.5% during the second quarter. Squarepoint Ops LLC now owns 63,384 shares of the company’s stock valued at $1,424,000 after acquiring an additional 33,554 shares in the last quarter. Arizona State Retirement System raised its stake in shares of Artivion by 6.2% during the second quarter. Arizona State Retirement System now owns 11,709 shares of the company’s stock valued at $263,000 after acquiring an additional 684 shares in the last quarter. Corient Private Wealth LP bought a new stake in shares of Artivion during the second quarter valued at approximately $3,581,000. Finally, Susquehanna International Group LLP boosted its holdings in shares of Artivion by 584.1% in the second quarter. Susquehanna International Group LLP now owns 102,531 shares of the company’s stock valued at $2,304,000 after purchasing an additional 87,544 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Artivion Price Performance

AORT stock opened at $21.40 on Wednesday. Artivion has a 12 month low of $19.16 and a 12 month high of $48.25. The company has a 50-day moving average price of $25.18 and a 200 day moving average price of $26.57. The stock has a market cap of $1.04 billion, a PE ratio of -305.63 and a beta of 1.23. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82.

Artivion (NYSE:AORT – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. The firm had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Equities research analysts anticipate that Artivion will post 0.45 earnings per share for the current year.

Artivion Company Profile

(Get Free Report)

Artivion, Inc (NYSE: AORT) is a medical device company focused on products and services for cardiac and vascular surgery. The company develops, manufactures and distributes implantable devices, surgical adhesives and preserved human tissues used in the treatment of complex cardiovascular conditions.

Its product portfolio includes On-X mechanical heart valves and related repair technologies, BioGlue surgical adhesive, aortic stent grafts and other devices for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in surgical procedures.

The company was formerly known as CryoLife, Inc and adopted the Artivion name in 2021 to reflect its broader focus on cardiovascular and aortic therapies.